Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Neurocrine Biosciences in-licenses clinical compound
August 2007
SHARING OPTIONS:

SAN DIEGOŚNeurocrine Biosciences Inc. recently announced it entered into an exclusive worldwide licensing agreement for the development and commercialization of valnoctamide stereoisomers with Yissum Research Development Co. of the Hebrew University of Jerusalem, Israel. Valnoctamide and its individual stereoisomers have been shown to be active in a number of preclinical models and have the potential to treat epilepsy, bipolar disease and neuropathic pain. "This stereoisomer of valnoctamide may provide the opportunity to address many of the current unmet medical needs in the area of neurology and psychiatry by offering patients and their physicians a unique new product profile. We look forward to initiating a clinical development program and plan to file our IND in the first half of 2008," says Christopher F. O'Brien, SVP and CMO of Neurocrine.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.